rfusin2-aml1
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT00718250)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rfusin2-aml1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00718250 | Phase 1 | May 1, 2008 | Elimination of Leukaemia Fund, Leukemia Research Foundation, University of London |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elimination of Leukaemia Fund | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Leukemia Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2008 |
3 organizations
Page 1 / 1